Lutathera<sup>®</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.
Hennrich U, Kopka K. · 2019
Read Lutathera<sup>®</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. by Hennrich U, Kopka K. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6789871.txt.
Description
Hennrich and Kopka review Lutathera, the first approved radiopharmaceutical for peptide receptor radionuclide therapy. Regulators in Europe approved it in 2017, the United States in 2018, and Canada in 2019. It treats gut and pancreatic neuroendocrine tumors that carry somatostatin receptors. The drug pairs the radionuclide lutetium-177 with a somatostatin-like targeting molecule, DOTA-TATE.
The radiation lands mainly on receptor-bearing tumor cells. Resulting DNA breaks, especially double-strand breaks, kill the cells. In the pivotal trial, at 20 months 65% of treated patients were alive without progression. Only 11% of the control group, on symptom treatment alone, matched that. The review lays out the therapy's concept and evidence.
Catalog record
| CREATOR | Hennrich U, Kopka K. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |